Medpace (MEDP) Competitors

Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.

Do institutionals and insiders believe in MEDP or IQV?

78.0% of Medpace shares are owned by institutional investors. Comparatively, 89.6% of IQVIA shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 1.6% of IQVIA shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Is MEDP or IQV more profitable?

Medpace has a net margin of 19.17% compared to IQVIA's net margin of 8.91%. Medpace's return on equity of 51.48% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	19.17%	51.48%	20.47%
IQVIA	8.91%	28.81%	7.02%

Which has better valuation & earnings, MEDP or IQV?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.16B	4.03	$404.39M	$13.10	23.07
IQVIA	$15.41B	1.73	$1.37B	$7.50	20.14

Which has more volatility and risk, MEDP or IQV?

Medpace has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500.

Does the media favor MEDP or IQV?

In the previous week, Medpace and Medpace both had 36 articles in the media. IQVIA's average media sentiment score of 0.82 beat Medpace's score of 0.61 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	18 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
IQVIA	18 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend MEDP or IQV?

Medpace presently has a consensus price target of $349.30, indicating a potential upside of 15.57%. IQVIA has a consensus price target of $237.62, indicating a potential upside of 57.34%. Given IQVIA's stronger consensus rating and higher probable upside, analysts clearly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
IQVIA	0 Sell rating(s)	7 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	2.75

Does the MarketBeat Community prefer MEDP or IQV?

IQVIA received 330 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 68.16% of users gave IQVIA an outperform vote while only 62.81% of users gave Medpace an outperform vote.

Company	Underperform	Outperform
Medpace	Outperform Votes 353 62.81%	Underperform Votes 209 37.19%
IQVIA	Outperform Votes 683 68.16%	Underperform Votes 319 31.84%

Summary

IQVIA beats Medpace on 10 of the 17 factors compared between the two stocks.